Hematopoiesis News Volume 12.14 | Apr 20 2021

    By
    Justin.choi
    -
    0
    22







    2021-04-20 | HN 12.14


    Hematopoiesis News by STEMCELL Technologies
    Vol. 12.14 – 20 April, 2021
    TOP STORY

    Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

    Researchers report findings in 23 patients who presented with thrombosis and thrombocytopenia 6 to 24 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine
    [New England Journal of Medicine]

    Full Article
    Survey results on the insights and hurdles of CRISPR genome editing.
    PUBLICATIONSRanked by the impact factor of the journal

    SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243

    Investigators report that TAK-243, a first-in-class ubiquitin activating enzyme UBA1 inhibitor in clinical development, caused preferential cytotoxicity in SLFN11-knock out cells.
    [Cancer Research]

    Abstract

    GPR182 Is an Endothelium-Specific Atypical Chemokine Receptor That Maintains Hematopoietic Stem Cell Homeostasis

    In constitutive GPR182-deficient mice, as well as after induced endothelium-specific loss of GPR182, researchers found significant increases in the plasma levels of CXCL10, CXCL12, and CXCL13.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Full Article

    Isoform-Specific and Signaling-Dependent Propagation of Acute Myeloid Leukemia by Wilms Tumor 1

    Scientists showed that the transcription factor Wilms tumor 1 formed a major node in the rewired mutation-specific gene regulatory networks of multiple acute myeloid leukemia subtypes.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Selenomethionine Protects Hematopoietic Stem/Progenitor Cells against Cobalt Nanoparticles by Stimulating Antioxidant Actions and DNA Repair Functions

    The authors investigated the mechanism underlying the toxic effect of cobalt nanoparticles (CoNPs) on HSCs/hematopoietic progenitor cells and to determine the protective effect of selenomethionine against CoNPs in vitro and in vivo.
    [Aging]

    Full Article

    The USP7-TRIM27 Axis Mediates Non-Canonical PRC1.1 Function and Is a Druggable Target in Leukemia

    In an attempt to unravel functionality of the non-canonical PRC1.1 Polycomb complex in human leukemogenesis, the authors showed that USP7 and TRIM27 were integral components of PRC1.1.
    [iScience]

    AbstractFull ArticleGraphical Abstract

    Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

    High-throughput TCRβ) sequencing was performed in 77 longitudinal samples from 26 chronic lymphocytic leukemia patients treated with ibrutinib.
    [Clinical Cancer Research]

    Abstract

    A Phase I/II Study of the Combination of Quizartinib with Azacitidine or Low-Dose Cytarabine for the Treatment of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

    In an open-label Phase I/II trial, patients of any age receiving first-salvage treatment for FLT3-ITD acute myeloid leukemia (AML) or age >60 years with untreated myelodysplastic syndrome or AML were treated with quizartinib plus azacitidine or low-dose cytarabine.
    [Haematologica]

    Abstract

    Mesenchymal Stem Cells Enhance the Impact of KIR Receptor-Ligand Mismatching on Acute Graft-versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia but Not in Those with Acute Lymphocytic Leukemia

    To investigate the potential influence of killer cell immunoglobulin‐like receptor (KIR) matching and mesenchymal stem cells, and their synergism on acute and chronic graft‐versus‐host disease after allo‐hematopoietic stem cell transplantation in acute myeloid leukemia and acute lymphoblastic leukemia patients.
    [Hematological Oncology]

    Abstract
    Request your free copy of the 'Bone Marrow Niches and HSC Fates' Wallchart
    REVIEWS

    Stem Cell Concepts in Myelodysplastic Syndromes: Lessons and Challenges

    The clinical importance of myelodysplastic syndromes (MDS) stem cells has been highlighted through the demonstration of selective persistence of MDS stem cells in patients at complete remission in response to therapy.
    [Journal of Internal Medicine]

    Abstract

    Treatment of Acute Myeloid Leukemia in Children: A Practical Perspective

    New approaches to hematopoietic stem cell transplantation, including the use of haploidentical donors, are significantly expanding donor options for patients with high‐risk acute myeloid leukemia.
    [Pediatric Blood & Cancer]

    Abstract
    INDUSTRY AND POLICY NEWS

    Incyte and MorphoSys Announce First Patient Dosed in Phase III inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

    Incyte and MorphoSys AG announced the first patient has been dosed in the placebo-controlled Phase III inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma.
    [Incyte]

    Press Release

    Vincerx Pharma Announces FDA Clearance of IND for Phase Ib Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome

    Vincerx Pharma, Inc. announced that the FDA has cleared the company’s Investigational New Drug Application to initiate a Phase Ib dose escalation study evaluating VIP152, a highly selective PTEFb/CDK9 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and Richter syndrome.
    [Vincerx Pharma, Inc.]

    Press Release
    FEATURED EVENT

    ISSCR: Stem Cells and Regenerative Medicine

    January 12 – 14, 2022
    Shanghai, China

    > See All Events

    JOB OPPORTUNITIES

    Research Scientist – Cancer Flow Cytometry

    Memorial Sloan Kettering Cancer Center – New York, New York, United States/p>

    Postdoctoral Fellow or Research Scientist – Cell and Gene Therapy of Cancer

    Rutgers University – New Brunswick, New Jersey, United States

    Journal Editor – Blood Cancer Discovery and Cancer Immunology

    American Association for Cancer Research – Boston, Massachusetts, United States

    Postdoctoral Fellow – Myeloma Tumor Microenvironment

    Moores Cancer Center – La Jolla, California, United States

    Editor – Hematology

    American Society of Hematology – Flexible

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter